在晚期肝细胞癌中对Nivolumab加Ipilimumab的器官特异反应:一个多中心的回顾性研究
Jung Sun Kim1,2, Youngun Kim2, Beodeul Kang1
1Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.
Cancer medicine
|June 9, 2025
概括
在没有先前免疫检查点抑制剂 (ICI) 暴露的晚期肝细胞癌 (HCC) 患者中,nivolumab加上ipilimumab的联合治疗显示出改善的肝脏反应. 这种组合有可能在HCC治疗中克服肝脏免疫耐受性.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 肝细胞癌研究 肝细胞癌研究
背景情况:
- 免疫检查点抑制剂 (ICI) 单疗对晚期肝细胞癌 (HCC) 的疗效有限,特别是在肝脏内反应方面.
- 研究器官特异性客观反应率 (OSORR) 对于优化治疗策略至关重要.
研究的目的:
- 为了比较nivolumab加上ipilimumab (Nivo/Ipi) 组合疗法的器官特异性客观响应率 (OSORR) 与晚期HCC的nivolumab (Nivo) 单疗法.
- 评估之前ICI暴露对治疗反应的影响.
主要方法:
- 在五个韩国癌症中心分析了204例Nivo/Ipi治疗患者的病变和305例Nivo治疗高级HCC患者的病变.
- 响应评估标准在固体瘤中的应用 1.1 对特定器官的响应评估 (肝脏,肺,淋巴结,其他部位).
主要成果:
- 与Nivo单独治疗 (13.5%和25.3%) 相比,Nivo/Ipi在肝脏 (18.1%) 和肺部 (17.7%) 显示出更高的OSORR.
- 没有先前ICI暴露的患者与先前暴露的患者相比,Nivo/Ipi (肝脏:29.0%,肺部:31.3%) 的OSORR显著更好 (肝脏:11.5%,肺部:11.4%).
- 肝脏或肺部的反应与改善的无进展和整体存活率相关.
结论:
- 在没有先前ICI暴露的HCC患者中,Nivolumab加Ipilimumab组合疗法提供了优异的肝内反应.
- 这种组合疗法在克服HCC肝脏特异性免疫耐受性方面表现有前途.
更多相关视频
11:08Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
708
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
5.1K
相关概念视频
Tumor Immunotherapy
489
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
489
Cytotoxic T Cells-mediated Immune Response
857
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
857
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
